HULIO

Approval Id: e8e7cf3b5224fd9a
Drug Approval Canada Name: HULIO
Product Name: HULIO
Status: Marketed
Status Date: 2024-06-05
Original Market Date: 2022-04-11
Din: 02502380
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 90:24.16.92
Atc Original: L04AB04 ADALIMUMAB
Atc Name: l 04 ab 04
Aig Number: 0150364003
Company Name: Biosimilar Collaborations Ireland Ltd.
Company Address: UNIT 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Dublin, --, Ireland, D13R20R
Company Detail Path: /organization/biosimilar-collaborations-ireland-ltd

ADALIMUMAB

20 MG / 0.4 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

e8e7cf3b5224fd9a

Type

Standard